An ASCO preview: What to watch for at cancer research’s big meeting - Takeaways - MDSpire

An ASCO preview: What to watch for at cancer research’s big meeting

  • By

  • Adam Feuerstein

  • May 28, 2026

Share

  • 1

    The ASCO annual meeting will feature key presentations, including Revolution Medicines' daraxonrasib for advanced pancreatic cancer.

  • 2

    Daraxonrasib showed a median overall survival of 13.2 months, significantly higher than the 6.7 months for standard chemotherapy.

  • 3

    Akeso's ivonescimab will present results from the Phase 3 HARMONi-6 study, focusing on newly diagnosed squamous non-small cell lung cancer.

  • 4

    Investor expectations for ivonescimab include a 20%-30% reduction in the risk of death compared to tislelizumab.

  • 5

    Bristol Myers Squibb will report results from the Phase 3 SUCCESSOR-2 study of mezigdomide in multiple myeloma at ASCO.

Original Source(s)

An ASCO preview: What to watch for at cancer research’s big meeting

  • by Adam Feuerstein

  • May 28, 2026

Related Content

Effects of donor killer-cell immunoglobulin-like receptor genotypes on clinical outcome after allogeneic hematopoietic stem cell transplantation—a systematic review and meta-analysis

T cell-mediated immune function in gastric cancer: a bibliometric overview of the last 20 years (2006-2025)

Beyond the dose-volume histogram: a critical appraisal of normal tissue complication probability modelling for osteoradionecrosis of the jaw and a strategic framework for clinical translation